Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab plus Chemotherapy in Locally Advanced Gastric Cancer
NCT06284746Phase 2Recruiting
- Start
- Oct 2023
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in gastric cancer (GC). Started Oct 2023; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT06284746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284746.